← Human Trials & Peer-Reviewed Studies
Subjects with high fasting insulin also have higher postprandial GLP-1 and glucagon levels than controls with lower insulin
Plain-language guide to PMID 31759769 (2019): crossover randomized controlled trial study of Glucagon in 14 women.
Key Facts
- PMID
- 31759769
- Journal
- Nutrition research (New York, N.Y.)
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Albinsson-Stenholm E et al. (6 authors)
- DOI
- 10.1016/j.nutres.2019.10.009
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Glucagon.
Little is known about postprandial release of serum ghrelin, glucagon, and glucagon-like peptide-1 (GLP-1) in relation with differing fasting insulin levels.
The researchers hypothesized that these hormones are affected by insulin resistance, and hence, the researchers compared different postprandial responses of GLP-1, glucagon, and ghrelin in subjects with relatively high (RHI) or relatively low (RLI) fasting insulin levels.
Who Took Part
The abstract describes 14 women taking part.
The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized and crossover.
Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In the crossover set-up each of the women took both Glucagon and the comparison in turn, acting as their own control.
What Was Measured
Little is known about postprandial release of serum ghrelin, glucagon, and glucagon-like peptide-1 (GLP-1) in relation with differing fasting insulin levels.
The researchers hypothesized that these hormones are affected by insulin resistance, and hence, the researchers compared different postprandial responses of GLP-1, glucagon, and ghrelin in subjects with relatively high (RHI) or relatively low (RLI) fasting insulin levels.
The subject headings attached to it are Fasting, Glucagon, Glucagon-Like Peptide 1, Insulin and Postprandial Period.
Author keywords: Carbohydrate content, Ghrelin, Glucagon-like peptide-1, Meal distribution and Satiety.
What This Means in Plain Language
The paper is a randomized and crossover study of Glucagon in 14 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2019 (Nutrition research (New York, N.Y.)), a journal based in United States.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.